Peringatan Keamanan

Patients experiencing an overdose may present with hypocalcemia, vomiting, parasthesia, and diarrhea.L13901 Overdose can be treated with symptomatic and supportive treatment that may include management of electrolyte imbalances and intravenous calcium gluconate.L13901

Etidronic acid

DB01077

small molecule approved

Deskripsi

Etidronic acid is a first generation bisphosphonate similar to clodronic acid and tiludronic acid.A203111 These drugs were developed to mimic the action of pyrophosphate, a regulator of calcification and decalcification.A1923 Etidronate’s use has decreased over the years in favor of the third generation, nitrogen containing bisphosphonate zoledronic acid, ibandronic acid, minodronic acid, and risedronic acid.A203111

Etidronic acid was granted FDA approval on 1 September 1977.L13901

Struktur Molekul 2D

Berat 206.0282
Wujud solid

Peta Jejaring Molekuler
Legenda: Obat • Target • Gen • Enzim • (Panah → menunjukkan arah efek / relasi) • Transporter • Carrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) The half life of etidronate is approximately 1-6 hours.[A203357,L13901]
Volume Distribusi Etidronic acid has a volume of distribution of 0.3-1.3L/kg.[A203357]
Klirens (Clearance) Etidronic acid has a renal clearance of 0.09L/kg/h.[A203357]

Absorpsi

Etidronic acid has an oral bioavailability of 1-10%.A203357 Further data regarding pharmacokinetics of etidronic acid are not readily available.A203357,L13901

Metabolisme

Etidronic acid is not metabolized in vivo

Rute Eliminasi

Absorbed etidronic acid is eliminated in the urine, while the unabsorbed drug is eliminated in the feces.L13901

Interaksi Makanan

3 Data
  • 1. Avoid multivalent ions. Separate administration from multivalent ions by at least two hours.
  • 2. Take on an empty stomach.
  • 3. Take with a full glass of water.

Interaksi Obat

328 Data
Deferasirox The risk or severity of gastrointestinal bleeding and gastrointestinal ulceration can be increased when Etidronic acid is combined with Deferasirox.
Bevacizumab The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Bevacizumab is combined with Etidronic acid.
Lenalidomide The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Lenalidomide is combined with Etidronic acid.
Thalidomide The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Thalidomide is combined with Etidronic acid.
Sunitinib The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Sunitinib is combined with Etidronic acid.
Ranibizumab The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Ranibizumab is combined with Etidronic acid.
Fumagillin The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Fumagillin is combined with Etidronic acid.
Resveratrol The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Resveratrol is combined with Etidronic acid.
Halofuginone The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Halofuginone is combined with Etidronic acid.
Anecortave acetate The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Anecortave acetate is combined with Etidronic acid.
Endostatin The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Endostatin is combined with Etidronic acid.
Semaxanib The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Semaxanib is combined with Etidronic acid.
Squalamine The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Squalamine is combined with Etidronic acid.
Pazopanib The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Pazopanib is combined with Etidronic acid.
Volociximab The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Volociximab is combined with Etidronic acid.
TNP-470 The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when TNP-470 is combined with Etidronic acid.
Pomalidomide The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Pomalidomide is combined with Etidronic acid.
Roquinimex The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Roquinimex is combined with Etidronic acid.
Endostar The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Endostar is combined with Etidronic acid.
Trebananib The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Trebananib is combined with Etidronic acid.
Anecortave The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Anecortave is combined with Etidronic acid.
Beloranib The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Beloranib is combined with Etidronic acid.
Brolucizumab The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Brolucizumab is combined with Etidronic acid.
Pantoprazole The therapeutic efficacy of Etidronic acid can be decreased when used in combination with Pantoprazole.
Omeprazole The therapeutic efficacy of Etidronic acid can be decreased when used in combination with Omeprazole.
Lansoprazole The therapeutic efficacy of Etidronic acid can be decreased when used in combination with Lansoprazole.
Esomeprazole The therapeutic efficacy of Etidronic acid can be decreased when used in combination with Esomeprazole.
Rabeprazole The therapeutic efficacy of Etidronic acid can be decreased when used in combination with Rabeprazole.
Dexlansoprazole The therapeutic efficacy of Etidronic acid can be decreased when used in combination with Dexlansoprazole.
Dexrabeprazole The therapeutic efficacy of Etidronic acid can be decreased when used in combination with Dexrabeprazole.
Ilaprazole The therapeutic efficacy of Etidronic acid can be decreased when used in combination with Ilaprazole.
Icosapent The risk or severity of gastrointestinal bleeding can be increased when Icosapent is combined with Etidronic acid.
Mesalazine The risk or severity of nephrotoxicity and hypocalcemia can be increased when Mesalazine is combined with Etidronic acid.
Indomethacin The risk or severity of gastrointestinal bleeding can be increased when Indomethacin is combined with Etidronic acid.
Nabumetone The risk or severity of gastrointestinal bleeding can be increased when Nabumetone is combined with Etidronic acid.
Ketorolac The risk or severity of gastrointestinal bleeding can be increased when Ketorolac is combined with Etidronic acid.
Tenoxicam The risk or severity of gastrointestinal bleeding can be increased when Tenoxicam is combined with Etidronic acid.
Celecoxib The risk or severity of gastrointestinal bleeding can be increased when Celecoxib is combined with Etidronic acid.
Tolmetin The risk or severity of gastrointestinal bleeding can be increased when Tolmetin is combined with Etidronic acid.
Rofecoxib The risk or severity of gastrointestinal bleeding can be increased when Rofecoxib is combined with Etidronic acid.
Piroxicam The risk or severity of gastrointestinal bleeding can be increased when Piroxicam is combined with Etidronic acid.
Fenoprofen The risk or severity of gastrointestinal bleeding can be increased when Fenoprofen is combined with Etidronic acid.
Valdecoxib The risk or severity of gastrointestinal bleeding can be increased when Valdecoxib is combined with Etidronic acid.
Diclofenac The risk or severity of gastrointestinal bleeding can be increased when Diclofenac is combined with Etidronic acid.
Sulindac The risk or severity of gastrointestinal bleeding can be increased when Sulindac is combined with Etidronic acid.
Flurbiprofen The risk or severity of gastrointestinal bleeding can be increased when Flurbiprofen is combined with Etidronic acid.
Etodolac The risk or severity of gastrointestinal bleeding can be increased when Etodolac is combined with Etidronic acid.
Mefenamic acid The risk or severity of gastrointestinal bleeding can be increased when Mefenamic acid is combined with Etidronic acid.
Naproxen The risk or severity of gastrointestinal bleeding can be increased when Naproxen is combined with Etidronic acid.
Sulfasalazine The risk or severity of gastrointestinal bleeding can be increased when Sulfasalazine is combined with Etidronic acid.
Phenylbutazone The risk or severity of gastrointestinal bleeding can be increased when Phenylbutazone is combined with Etidronic acid.
Meloxicam The risk or severity of gastrointestinal bleeding can be increased when Meloxicam is combined with Etidronic acid.
Carprofen The risk or severity of gastrointestinal bleeding can be increased when Carprofen is combined with Etidronic acid.
Diflunisal The risk or severity of gastrointestinal bleeding can be increased when Diflunisal is combined with Etidronic acid.
Salicylic acid The risk or severity of gastrointestinal bleeding can be increased when Salicylic acid is combined with Etidronic acid.
Meclofenamic acid The risk or severity of gastrointestinal bleeding can be increased when Meclofenamic acid is combined with Etidronic acid.
Acetylsalicylic acid The risk or severity of gastrointestinal bleeding can be increased when Acetylsalicylic acid is combined with Etidronic acid.
Oxaprozin The risk or severity of gastrointestinal bleeding can be increased when Oxaprozin is combined with Etidronic acid.
Ketoprofen The risk or severity of gastrointestinal bleeding can be increased when Ketoprofen is combined with Etidronic acid.
Balsalazide The risk or severity of gastrointestinal bleeding can be increased when Balsalazide is combined with Etidronic acid.
Ibuprofen The risk or severity of gastrointestinal bleeding can be increased when Ibuprofen is combined with Etidronic acid.
Olsalazine The risk or severity of nephrotoxicity and hypocalcemia can be increased when Olsalazine is combined with Etidronic acid.
Lumiracoxib The risk or severity of gastrointestinal bleeding can be increased when Lumiracoxib is combined with Etidronic acid.
Magnesium salicylate The risk or severity of gastrointestinal bleeding can be increased when Magnesium salicylate is combined with Etidronic acid.
Salsalate The risk or severity of gastrointestinal bleeding can be increased when Salsalate is combined with Etidronic acid.
Choline magnesium trisalicylate The risk or severity of gastrointestinal bleeding can be increased when Choline magnesium trisalicylate is combined with Etidronic acid.
Antrafenine The risk or severity of gastrointestinal bleeding can be increased when Antrafenine is combined with Etidronic acid.
Aminophenazone The risk or severity of gastrointestinal bleeding can be increased when Aminophenazone is combined with Etidronic acid.
Antipyrine The risk or severity of gastrointestinal bleeding can be increased when Antipyrine is combined with Etidronic acid.
Tiaprofenic acid The risk or severity of gastrointestinal bleeding can be increased when Tiaprofenic acid is combined with Etidronic acid.
Etoricoxib The risk or severity of gastrointestinal bleeding can be increased when Etoricoxib is combined with Etidronic acid.
Taxifolin The risk or severity of gastrointestinal bleeding can be increased when Taxifolin is combined with Etidronic acid.
Oxyphenbutazone The risk or severity of gastrointestinal bleeding can be increased when Oxyphenbutazone is combined with Etidronic acid.
Licofelone The risk or severity of gastrointestinal bleeding can be increased when Licofelone is combined with Etidronic acid.
Nimesulide The risk or severity of gastrointestinal bleeding can be increased when Nimesulide is combined with Etidronic acid.
Benoxaprofen The risk or severity of gastrointestinal bleeding can be increased when Benoxaprofen is combined with Etidronic acid.
Metamizole The risk or severity of nephrotoxicity and hypocalcemia can be increased when Metamizole is combined with Etidronic acid.
Zomepirac The risk or severity of gastrointestinal bleeding can be increased when Zomepirac is combined with Etidronic acid.
Cimicoxib The risk or severity of gastrointestinal bleeding can be increased when Cimicoxib is combined with Etidronic acid.
Lornoxicam The risk or severity of gastrointestinal bleeding can be increased when Lornoxicam is combined with Etidronic acid.
Aceclofenac The risk or severity of gastrointestinal bleeding can be increased when Aceclofenac is combined with Etidronic acid.
Zaltoprofen The risk or severity of gastrointestinal bleeding can be increased when Zaltoprofen is combined with Etidronic acid.
Azapropazone The risk or severity of gastrointestinal bleeding can be increased when Azapropazone is combined with Etidronic acid.
Parecoxib The risk or severity of gastrointestinal bleeding can be increased when Parecoxib is combined with Etidronic acid.
Salicylamide The risk or severity of gastrointestinal bleeding can be increased when Salicylamide is combined with Etidronic acid.
Kebuzone The risk or severity of gastrointestinal bleeding can be increased when Kebuzone is combined with Etidronic acid.
Isoxicam The risk or severity of gastrointestinal bleeding can be increased when Isoxicam is combined with Etidronic acid.
Indoprofen The risk or severity of gastrointestinal bleeding can be increased when Indoprofen is combined with Etidronic acid.
Ibuproxam The risk or severity of gastrointestinal bleeding can be increased when Ibuproxam is combined with Etidronic acid.
Floctafenine The risk or severity of gastrointestinal bleeding can be increased when Floctafenine is combined with Etidronic acid.
Fenbufen The risk or severity of gastrointestinal bleeding can be increased when Fenbufen is combined with Etidronic acid.
Etofenamate The risk or severity of gastrointestinal bleeding can be increased when Etofenamate is combined with Etidronic acid.
Epirizole The risk or severity of gastrointestinal bleeding can be increased when Epirizole is combined with Etidronic acid.
Benzydamine The risk or severity of gastrointestinal bleeding can be increased when Benzydamine is combined with Etidronic acid.
Dexibuprofen The risk or severity of gastrointestinal bleeding can be increased when Dexibuprofen is combined with Etidronic acid.
Dexketoprofen The risk or severity of gastrointestinal bleeding can be increased when Dexketoprofen is combined with Etidronic acid.
Droxicam The risk or severity of gastrointestinal bleeding can be increased when Droxicam is combined with Etidronic acid.
Tolfenamic acid The risk or severity of gastrointestinal bleeding can be increased when Tolfenamic acid is combined with Etidronic acid.
Firocoxib The risk or severity of gastrointestinal bleeding can be increased when Firocoxib is combined with Etidronic acid.
Clonixin The risk or severity of gastrointestinal bleeding can be increased when Clonixin is combined with Etidronic acid.

Target Protein

Hydroxylapatite
Receptor-type tyrosine-protein phosphatase S PTPRS
V-type proton ATPase catalytic subunit A ATP6V1A
ADP/ATP translocase 1 SLC25A4
ADP/ATP translocase 2 SLC25A5
ADP/ATP translocase 3 SLC25A6

Referensi & Sumber

Synthesis reference: Rogovin, L.,Brawn, D.P. and Kalberg, AN.; US. Patent 3,400,147; September 3,1968; assigned to The Procter & Gamble Co.
Artikel (PubMed)
  • PMID: 30650219
    Cremers S, Drake MT, Ebetino FH, Bilezikian JP, Russell RGG: Pharmacology of bisphosphonates. Br J Clin Pharmacol. 2019 Jun;85(6):1052-1062. doi: 10.1111/bcp.13867. Epub 2019 Feb 28.
  • PMID: 18214569
    Russell RG, Watts NB, Ebetino FH, Rogers MJ: Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. Osteoporos Int. 2008 Jun;19(6):733-59. doi: 10.1007/s00198-007-0540-8.
  • PMID: 9145236
    Murakami H, Takahashi N, Tanaka S, Nakamura I, Udagawa N, Nakajo S, Nakaya K, Abe M, Yuda Y, Konno F, Barbier A, Suda T: Tiludronate inhibits protein tyrosine phosphatase activity in osteoclasts. Bone. 1997 May;20(5):399-404.
  • PMID: 8573422
    Sansom LN, Necciari J, Thiercelin JF: Human pharmacokinetics of tiludronate. Bone. 1995 Nov;17(5 Suppl):479S-483S.
  • PMID: 7858370
    Dunn CJ, Fitton A, Sorkin EM: Etidronic acid. A review of its pharmacological properties and therapeutic efficacy in resorptive bone disease. Drugs Aging. 1994 Dec;5(6):446-74. doi: 10.2165/00002512-199405060-00006.
  • PMID: 21555003
    Russell RG: Bisphosphonates: the first 40 years. Bone. 2011 Jul;49(1):2-19. doi: 10.1016/j.bone.2011.04.022. Epub 2011 May 1.

Contoh Produk & Brand

Produk: 25 • International brands: 1
Produk
  • Act Etidrocal
    Tablet • - • Oral • Canada • Approved
  • Act Etidronate
    Tablet • 200 mg • Oral • Canada • Approved
  • Act Etidronate
    Tablet • 400 mg • Oral • Canada • Approved
  • Apo-etidronate
    Tablet • 200 mg • Oral • Canada • Generic • Approved
  • Apo-etidronate
    Tablet • 400 mg • Oral • Canada • Generic • Approved
  • Didrocal
    Kit; Tablet • - • Oral • Canada • Approved
  • Didronel
    Tablet • 400 mg/1 • Oral • US • Approved
  • Didronel
    Tablet • 400 mg/1 • Oral • US • Approved
Menampilkan 8 dari 25 produk.
International Brands
  • Etidron — Gentili

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul